Phase II Study of Everolimus (RAD001, Afinitor(R)) for Children With Recurrent or Progressive Ependymoma

Trial Profile

Phase II Study of Everolimus (RAD001, Afinitor(R)) for Children With Recurrent or Progressive Ependymoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Ependymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 20 Jan 2015 Planned End Date changed from 1 Sep 2017 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top